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Abstract
Introduction Traditionally, surgical pathology reports are narrative. These report types are prone to error and missing data;
therefore, structured standardized reporting was introduced. However, the effect of synoptic reporting on the completeness of
esophageal and gastric carcinoma pathology reports is not yet established.
Materials and methods A population-based retrospective nationwide cohort study in the Netherlands was conducted over a
period of 2012–2016, utilizing the Netherlands Cancer Registry for patient data and the nationwide network and registry of
histology for pathology data.
Results In total, 1148 narrative and 1311 synoptic pathology reports were included. Completeness was achieved in 56.4% of the
narrative reports versus 97.0% of the synoptic reports (p < 0.01). Out of 21 standard items, 15 were significantly more frequently
reported in synoptic reports.
Conclusion Synoptic reporting improves surgical pathology reporting quality and should be implemented in standard patient
care.
Keywords Pathology report . Synoptic . Surgical pathology . Narrative
Introduction
Traditionally, surgical pathology reports are narrative, mean-
ing they are written without a fixed form or structured outline
[1]. Narrative reporting (NR), however, is prone to error, miss-
ing data, and inferior readability [2].
In 1991, the idea of a synoptic pathology format was intro-
duced, meaning that completing a standardized structured
form based on relevant and up-to-date guidelines will create
a pathology report [1, 3]. Since its introduction, several studies
have reported that synoptic or structured standardized
reporting (SSR) significantly improves report completeness
[4, 5]. Audits show that for esophageal carcinoma (EC) and
gastric carcinoma (GC) narrative pathology reports complete-
ness is an issue, in particular for resection margins and TNM
stage [6]. Therefore, the College of American Pathologists’
esophageal and gastric oncology guidelines advise the use of
SSR for pathology reporting [7, 8].
The main objective of this study is to assess the effect of
SSR on the completeness of esophageal and gastric carcinoma
pathology reports. We hypothesize that SSR will improve the
completeness of reporting [9].
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Materials and methods
Participants
A population-based retrospective nationwide cohort study
was conducted including surgically treated patients with pri-
mary gastric or esophageal cancer, diagnosed between
January 2012 and January 2016. Patient data, as registered
by the Netherlands Cancer Registry (NCR), were linked to
corresponding pathology report data from the nationwide net-
work and registry of histo- and cytopathology in the
Netherlands (Pathologisch-Anatomisch Geautomatiseerd
Landelijk Archief; PALGA) [10]. Since not whole pathology
reports, but only conclusion texts are available for research
purposes via PALGA, we combined PALGA data with NCR
patient data to ensure completeness of our data. All data has
been anonymized.
Surgical pathology reports concerning EC and GC types
15.0 to 15.9 and 16.0 to 16.9 respectively, according to the
10th edition of International Classification of Disease (ICD),
were included in the study. The period 2014–2016 was select-
ed, since both SSR and NR were used during that period, with
SSR for EC and GC being gradually introduced in
March 2014 in the Netherlands. Narrative pathology reports
from the cohorts 2012 and 2013 were added as a separate
reference group. The small number of SSR in this period of
introduction (n = 45) were not included in further analyses.
Exclusion criteria were endomucosal excisions, more than
one primary tumor described, malignancy primarily originat-
ing from other tissue than esophageal or gastric tissue, and
biopsy, i.e., non-surgical, reports.
Primary outcome
The primary outcome was completeness, which was defined
as the inclusion of all items in the pathology report as recom-
mended by Dutch guidelines (www.oncoline.nl), comparable
to the guidelines of the College of American Pathologists’
(CAP) [7, 8]. Standard items for EC, to be present in pathol-
ogy reports are Bhistological type,^ Bdifferentiation grade,^
Binvasion depth,^ Bproximal/distal/circumferential resection
margin,^ Btotal and metastatic number of lymph nodes,^
Bsize,^ Blocation,^ and Btumor regression after neoadjuvant
therapy.^ Histological subtypes were based on the WHO clas-
sification and Lauren’s system [11, 12]. Standard items for GC
were identical, except for circumferential margin, since this is
not applicable for the stomach.
Differentiation grade is applied for grading squamous cell
carcinomas and intestinal adenocarcinomas according to the
WHO classification system [12]. The item Bsubtype of adeno-
carcinoma (AC)^ was only analyzed in adenocarcinomas.
BPerineural invasion,^ Blymphovascular invasion,^ and
Bsubtype of AC^ were regarded as optional items for both
carcinomas.
Secondary outcome
Completeness was also compared when pathology reports
were further grouped into academic and non-academic centers
regarding SSR.
Statistics
Statistical analysis was performed with the SPSS software
package, version 24.0 (SPSS Inc., IBM Corporation
Software Group, Somers, NY, USA). For dichotomous or or-
dinal variables, the Pearson’s chi-squared test or Fisher’s exact
test was used if appropriate. All tests were two-sided, and
p values less than 0.05 were considered to be statistically
significant.
Results
In total, 4838 pathology reports were included: 2379 (49.2%)
reference, 1311 (27.1%) synoptic and 1148 (23.7%) narrative
reports (Fig. 1). Regarding SSR, there was no statistical dif-
ference between the academic and non-academic setting in
complete reports for either EC or GC (both p = 0.80).
EC completeness (Table 1 and Fig. 2)
In total, 2858 EC pathology reports were included, 685 narra-
tive and 806 synoptic and 1367 in the reference cohort.
Completion was achieved in 450 (65.7%) narrative versus
789 (97.9%) synoptic reports (p < 0.01). Besides Bnumber of
lymph nodes^ and BT stage,^ which were comparable, all
standard items were significantly more frequently reported
in SSR. The difference in completeness between SSR and
NR did not affect the distribution of reported histological tu-
mor types in the EC group (p = 0.46): adenocarcinoma 890
(80.8%), squamous cell carcinoma 154 (14.0%), and other
types 57 (5.2%). Regarding optional items, SSR resulted in
a much higher percentage of reported Blymphovascular
invasion^ and Bperineural invasion^.
GC completeness (Table 1 and Fig. 2)
In total, 1980 GC pathology reports were included, of which
463 narrative, 505 synoptic and 1012 in the reference cohort.
In total, 197 (42.5%) NR were complete versus 483 (95.6%)
SSR (p < 0.01). BDifferentiation grade^ was significantly
more reported in SSR compared with NR (100% versus
89.3%, p < 0.01), whereas Binvasion depth,^ Bnumber of
lymph nodes,^ and Bhistological tumor type^ showed no
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significant difference between NR and SSR. Reporting of GC
histological tumor type, consisting mainly of adenocarcinoma
(864 (96.0%)), did not differ between SSR and NR; however,
Bsubtype of AC^ was less frequently reported with NR com-
pared with SSR (79.4% versus 95.9%, p < 0.01). The optional
items, Blymphovascular invasion^ and Bperineural invasion^
were much more frequently reported with SSR.
Missing dataMissing data in SSR was caused on one hand by
software-related issues in the early stages of implementation
(teething problems). For EC, 20%, and GC, 19% of the omit-
ted items were due to software-related factors. Also, in the
SSR software, differentiation grade is considered optional
when neoadjuvant therapy was given (since grading is not
possible in (sub-)total regression). On the other hand, the
option ofmanually turning off several features, including stan-
dard items, remained through all development stages. It re-
mains up to the pathologist whether he uses the complete
protocol and/or the standard pathology conclusion or not.
Discussion
This study shows that SSR increases the completeness of sur-
gical esophageal and gastric cancer resection pathology re-
ports, in particular for items as tumor size, grade, location,
tumor regression after neoadjuvant therapy. SSR also in-
creases lymphovascular invasion and perineural invasion
reporting. Essential items for staging including depth of inva-
sion, number of (metastasized) lymph nodes and tumor type
Reports from PALGA data from 
gastric and esophageal 
carcinomas 
( n=37,482 )
Tumor records
( n = 15,295 )
Patient data
Diagnosis 2012-2016 by NCR
( n = 15,556 )
Without surgical treatment
( n = 9,892 )
Endoscopic resection, 
polypectomy, wedge excision
( n = 505 )
2 primary tumors
( n = 11 ) 
Included pathology reports
( n = 4,838 )
NR ref
( n = 2,379 )
SSR 2012, 2013
( n = 45 )
SSR
( n = 1,311 )
NR
( n = 1148 )
Not originating from esophagus 
or stomach
( n = 4 ) 
Fig. 1 Flowchart depicting the
selection process for eligibility.
NR ref., narrative reports from the
period 2012, 2013 used as
reference; NR, narrative reports;
SSR, structured standardized
reports
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were present in almost all narrative reports, and only minimal
improvements could be achieved by SSR. For GC reporting
especially, SSR leads to an increase in the reporting of histo-
logical subtype of adenocarcinomas. This is clinically rele-
vant, since poorly cohesive adenocarcinomas (WHO) show
a different biological behavior resulting in different clinical
patient outcomes [13].
The differences between NR and SSR, regarding pathology
report completeness, are in line with the systematic review by
Sluijter et al. [1]. In accordance with Messenger et al., ours
show no difference between the non-academic and academic
care setting, looking at the effect of SSR on report complete-
ness [4], implying that report quality much less depends on the
pathologist’s specialization and, therefore, seems to help all
pathologists with their histopathology reports. Although im-
proved report completeness does not seem to have a direct
impact on adjuvant treatment in GC and EC, as is the case
in colorectal cancer—since the presence of lymph node
metastases and pT4 tumor stage necessitate adjuvant
therapy—this might very well change in the future. We do
not claim that the introduction of SSR is the only or main
factor for improved pathology reporting. Other factors, that
may have influenced awareness among Dutch pathologists
for EC/GC pathology reporting, are increased centralization
of gastro-esophageal oncological surgery, comparative feed-
back by the Dutch Upper GI Cancer Audit (DUCA) (https://
dica.nl/duca/) and monitoring during the multicenter gastric
cancer CRITICS trial [14].
To our knowledge, this is the first report on a nationwide
level with roughly 5000 pathology reports describing the in-
fluence of SSR on the completeness of EC/GC surgical pa-
thology reports. The data originate from a nationwide data-
base, which increases the power of the overall study, despite
its retrospective nature.
Furthermore, PALGA’s SSR software is considered to be
level 6 on the 1–6 reporting level and quality scale developed
Table 1 Completeness and standard items
Esophageal carcinoma Gastric carcinoma
Reference
N = 1367
NR
N = 685 (%)
SSR
N = 806 (%)
p value**** Reference
N = 1012
NR
N = 463 (%)
SSR
N = 505 (%)
p value****
Overall completeness 666 (48.7) 450 (65.7) 789 (97.9) < 0.01 349 (34.5) 197 (42.5) 483 (95.6) < 0.01
T stage 1338 (97.9) 678 (99.0) 804 (99.8) 0.09 1007 (99.5) 459 (99.1) 505 (100) 0.05
Number of lymph nodes* 1365 (99.9) 685 (100) 806 (100) – 1005 (99.3) 459 (99.1) 505 (100) 0.05
Histology type** 855 (97.9) 391 (97.5) 276 (100) 0.01 929 (98.5) 412 (99.0) 416 (99.8) 0.22
Subtype of AC1 315 (36.8) 194 (49.6) 149 (54.0) 0.27 668 (71.9) 327 (79.4) 399 (95.9) < 0.01
Differentiation grade*** 159 (72.3) 122 (84.1) 119 (97.5) < 0.01 214 (81.7) 125 (89.3) 206 (100) < 0.01
AC, adenocarcinoma
*Only Bnumber of lymph nodes^ are reported, since the Bnumber of positive lymph nodes^ resulted in exactly the same numbers
**Excluded were reports describing T0 and Tis carcinomas and subtotal regression after neoadjuvant therapy
***Included were reports describing squamous cell carcinoma or adenocarcinoma intestinal type
****NR versus SSR
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Fig. 2 Recommended and
optional items. LVI,
lymphovascular invasion; PI,
perineural invasion; PRM,
proximal resection margin; DRM,
distal resection margin; CRM,
circumferential resection margin;
regression, tumor regression after
neoadjuvant therapy; E-NR,
esophageal narrative reporting; E-
SSR, esophageal structured
standardized reporting; G-NR,
gastric narrative reporting; G-
SSR, gastric structured
standardized reporting
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by Shrigley et al., which scores pathology reporting on format,
content and several other quality indicators [15]. Level 1 cor-
responds to the traditional narrative report with a single text
field, manual abstraction and a report completion duration
within months to years after clinical procedure and level 6 to
the standardized structured report with common data and mes-
saging standards, discrete data fields, automated abstraction
and report completion within weeks after clinical procedure.
The fact that PALGA-software is considered level 6 makes it
reasonable to suggest that our results can at least partly be
attributed to the effect of using SSR [15].
Despite comparing reporting type on academic and non-
academic level, inter- and intra-pathologist reporting differ-
ences were not accounted for, which possibly could have af-
fected the completeness of reports [4].
In conclusion, our study has shown that SSR definitely
improves the quality of surgical pathology reports of EC/GC
and, therefore, should be part of standard patient care.
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